SPDR Series Trust SPDR S&P Biotech ETF
已更新

XBI Weekly

214
Positive reason for XBI - relatively equal weighted @ 1% - can not know which bio is going to be a winner!
Like the 30 week moving average as an indicator.
Thesis is as rates fall Bios will be more attractive!
Supply of new drugs in big pharma is dwindling/ coming off patent and they need to replace with new drugs for revenue; so Big Parma will be looking to acquire some of the potential winners - AKA MDGL
交易進行
Still cruising sideways as rates got another boost!

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。